is to cut up to 680 jobs in its development organization, which helps bring its drugs to market, the Swiss pharmaceuticals company said on Tuesday.
The job eliminations are separate from a restructuring program which could lead up to 8,000 of Novartis’s 78,000 global work force being cut, it said. Novartis currently employs around 12,500 in development which includes handling drug regulations, analytics, and support functions like quality assurance.
Around 3,000 of the roles are currently in Switzerland and 2,000 in the United States, meaning around 14 per cent of the positions in those countries will be affected.